Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.75 |
| ▸ | TFEB | P19484 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1397474 | 1.00 | NFE2L2 (0.75) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL10438847 | 0.87 | ALDH1A1 (0.58) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL69522 | 0.87 | ALDH1A1 (0.58) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL5598849 | 0.86 | NFE2L2 (1.00) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL5598851 | 0.86 | NFE2L2 (1.00) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Cyclopropane SCHEMBL11842187 | 0.85 | NFE2L2 (0.60) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL2744047 | 0.85 | NFE2L2 (1.00) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL30307386 | 0.85 | NFE2L2 (1.00) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL2744044 | 0.85 | NFE2L2 (1.00) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL29805195 | 0.85 | NFE2L2 (1.00) | NFE2L2TFEBKDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3208301-B1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORP (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-10126478-B2 | Resin composition and optical compensation film using same | TOSOH CORPORATION (JP) | 2018-11-13 | — | — | US | disclosed |
| US-20170242174-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | TOSOH CORPORATION (JP) | 2017-08-24 | — | — | US | disclosed |
| EP-3208301-A1 | RESIN COMPOSITION AND OPTICAL COMPENSATION FILM USING SAME | Tosoh Corporation (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20040235830-A1 | Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2000024742-A1 | PYRAZOLOPYRIDINE AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-04 | — | — | WO | disclosed |
| US-5382600-A | 3,3-diphenylpropylamines and pharmaceutical compositions thereof | PHARMACIA AKTIEBOLAG (SE) | 1995-01-17 | — | — | US | disclosed |
| EP-0325571-B1 | NEW AMINES, THEIR USE AND PREPARATION | Kabi Pharmacia AB (SE) | 1991-08-07 | — | — | EP | disclosed |
| EP-0354234-A1 | NEW AMINES, THEIR USE AND PREPARATION | KabiVitrum AB (SE) | 1990-02-14 | — | — | EP | disclosed |
| WO-1989006644-A1 | NEW AMINES, THEIR USE AND PREPARATION | KABIVITRUM AB (SE) | 1989-07-27 | — | — | WO | disclosed |
| EP-0325571-A1 | New amines, their use and preparation | Kabi Pharmacia AB (SE) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235830-A1 | Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases | CYP46A1, REN, CYP11B2 | NFE2L2 189/4885TFEB 774/4885KDM4E 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.